Abstract
Circulating Tumor Cells (CTC) are shed from primary or secondary tumors. Prior studies have demonstrated that enumeration of CTC is a robust independent prognostic factor of progression free and overall survival in patients with early and metastatic breast cancer. CTC, as well as other circulating tumor markers, have the appealing advantages over tissue biopsy of (1) ease of collection, (2) serial evaluation, and (3) interrogation of the entire tumor burden instead of just a limited part of the tumor. Advances have been recently made in phenotyping and genotyping of CTC, which should provide insights into the predictive role of CTC for sensitivity or resistance to therapies. In addition, CTC phenotypic marker changes during the course of treatment may serve as pharmacodynamic monitoring tools. Therefore, CTC may be considered “liquid biopsies,” providing prognostic and predictive clinical information as well as additional understanding of tumor heterogeneity.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564
Ashworth TR (1869) A case of cancer in which cells similar to those tumours were seen in the blood after death. Med J Aust 14:146–147
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489
Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414
Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18:5701–5710
Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR (2003) Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 162:149–155
Gascoyne PR, Noshari J, Anderson TJ, Becker FF (2009) Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30:1388–1398
Zheng S (2007) Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 1162:154–161
Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156:57–63
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904
Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W et al (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106:3970–3975
Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235–1239
Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC et al (2010) Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A 107:14524–14529
Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107:18392–18397
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580–584
Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C et al (2013) Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 8:735–741
Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162
Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F et al (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9:016003
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27:2177–2184
Stathopoulou A (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20:3404–3412
Ignatiadis M (2007) Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202
Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S et al (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 130:1590–1597
Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A et al (2010) Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102:276–284
Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P et al (2012) A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 41:1241–1250
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N et al (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 11:3–14
Micheel CM, Nass SJ, Omenn GS (2012). Evolution of translational omics: lessons learned and the path forward. The National Academies Press
Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452
Paoletti C, Hayes DF (2014) Molecular testing in breast cancer. Annu Rev Med 65:95–110
Harris L (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF et al (2011) NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9(Suppl 5):S1–32; quiz S3
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB et al (2013) Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:753–760; quiz 61
Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L et al (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695
Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106:dju066 doi:10.1093/jnci/dju066
Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P et al (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21:729–733
Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M et al (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16:2634–2645
Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U et al (2007) The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 18:1484–1492
Cohen SJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309
Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK et al (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30:525–532
Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM et al (2013) Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 19:1596–1602
Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W et al (2013) Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 32:179–188
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428
Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M et al (2011) Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 127:33–41
Bednarz-Knoll N, Alix-Panabieres C, Pantel K (2012) Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 31:673–687
Wicha MS (2006) Cancer stem cells and metastasis: lethal seeds—commentary. Clin Cancer Res 12:5606–5607
Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A et al (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178:989–996
Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K et al (2009) Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol 219:287–293
Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z (2001) Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 7:4080–4085
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA et al (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110–1122
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608
Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59:110–118
Mathew A, Brufsky AM, Davidson NE (2015) Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res 21:2421–2423
Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D et al (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11:R59
Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR et al (2011) Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 122:356–360
Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L et al (2011) Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 128:155–163
Babayan A, Hannemann J, Spotter J, Muller V, Pantel K, Joosse SA (2013) Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 8:e75038
Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N et al (2015) Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor positive breast cancer. Clin Cancer Res 21: 2487–2498
Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E et al (2015) Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol
Meng S (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393–9398.
Meng S (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103:17361–17365
Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C et al (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118:523–530
Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C et al (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6:e15624
Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M et al (2013) Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 7:680–692
Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M et al (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 16:5233–5243
Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG et al (2015) Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 21:2771–2779
de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P et al (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13:3611–3616
Payne RE, Yague E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B et al (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10:51–57
Kallergi G, Mavroudis D, Georgoulias V, Stournaras C (2007) Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13:79–88
Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA et al (2010) Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 16:1073–1084
Dawson SJ, Rosenfeld N, Caldas C (2013) Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 369:93–94
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112
Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ et al (2014) Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20:2643–2650
Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothe F, Ignatiadis M et al (2013) Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 108:1358–1367
Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L et al (2015) Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 9:749–757
Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC et al (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345:216–220
Schnipper L (1986) Clinical implications of tumor-cell heterogeneity. N Engl J Med 314:1423–1431
Hayes DF, Paoletti C (2013) Circulating tumour cells: insights into tumour heterogeneity. J Intern Med 274:137–143
Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N et al (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134:283–289
Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R et al (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115:581–590
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E et al (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47
Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U et al (2005) Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43:617–627
Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF (2008) Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 10:R69
Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G et al (2009) Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11:R39
Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ et al (2010) Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126:669–683
Acknowledgments
We gratefully acknowledge Celina Kleer, M.D. who provided the pathology images for Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Breast Cancer Research Foundation
About this chapter
Cite this chapter
Paoletti, C., Hayes, D. (2016). Circulating Tumor Cells. In: Stearns, V. (eds) Novel Biomarkers in the Continuum of Breast Cancer. Advances in Experimental Medicine and Biology(), vol 882. Springer, Cham. https://doi.org/10.1007/978-3-319-22909-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-22909-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22908-9
Online ISBN: 978-3-319-22909-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)